Abbott Laboratories (Abbott Laboratories) Total Current Assets : $22,670 Mil (As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

What is Abbott Laboratories Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Abbott Laboratories's total current assets for the quarter that ended in Dec. 2023 was $22,670 Mil.

Abbott Laboratories Total Current Assets Historical Data

The historical data trend for Abbott Laboratories's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Total Current Assets Chart

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

15,667.00

20,441.00

24,239.00

25,224.00

22,670.00

Abbott Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															24,377.00	23,505.00	22,664.00	22,670.00	-

Abbott Laboratories Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Abbott Laboratories's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	7279	+	8821	+	6570	+	0
	=	22,670

Abbott Laboratories's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	7279	+	8821	+	6570	+	0
	=	22,670

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Abbott Laboratories (NYSE:ABT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Abbott Laboratories's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7279	-	34387	+	0.75 * 6565	+	0.5 * 6570
=	-18,899

Abbott Laboratories Total Current Assets Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories (Abbott Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ABT:Mexico 0Q15:UK ABL:Germany ABL:Germany ABL:Germany ABL:Germany ABT:Chile ABT:Switzerland ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Executives

Andrea F Wainer	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr.	officer: VICE PRESIDENT	C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman	director	3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone	officer: EXECUTIVE VICE PRESIDENT	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau	officer: Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady	director	50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive	officer: Senior Vice President	100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt	officer: Executive Vice President	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck	officer: Vice President, Controller	100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092